Mark A. Hillman
Hillman Value Fund
Mark A. Hillman West Pharmaceutical Services Inc stake
total: 75
Hillman Value Fund WST trades
- Total transactions:
- 3
- New positions:
- 1
- Reduced:
- 2
- Held since:
- 2025 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Mark A. Hillman holds 8,900 West Pharmaceutical Services Inc (WST) shares with a market value of roughly $2.23M accounting for 2.69% of the overall portfolio. To date, the estimated cost basis is nearly $262.33 for "buy" trades and estimated average "sell" price is $262.59. Hillman Value Fund first purchased WST in 2025 Q3, initially acquiring 10,267 shares. Since the initial investment in West Pharmaceutical Services Inc (WST), Hillman Value Fund has made 2 more transactions.
When did Mark A. Hillman buy West Pharmaceutical Services Inc (WST)?
Mark A. Hillman first invested in West Pharmaceutical Services Inc (WST) in 2025 Q3 at the reported quarter-end price of $262.33 per share.
What's the cost basis of Hillman Value Fund's WST stake?
The estimated cost basis for West Pharmaceutical Services Inc (WST) stake is around $262.33 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $262.33
- Weighted AVG sell price:
- $262.59
Mark A. Hillman's historical trades in West Pharmaceutical Services Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.69%
|
8,900
|
$250.64
|
$2,230,696
|
-7.29% (-700)
|
-0.19%
|
|
2025 Q4
|
2.82%
|
9,600
|
$275.14
|
$2,641,344
|
-6.50% (-667)
|
-0.17%
|
|
2025 Q3
|
2.56%
|
10,267
|
$262.33
|
$2,693,342
|
new
|
+2.56%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.